Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citrus e fructibus + cydonia e fructibus (commonly known by the brand name Gencydo) is an anthroposophic combination preparation derived from lemon (*Citrus medica* ssp. *limonum*) and quince (*Cydonia oblonga*) fruit extracts. Developed by WALA Heilmittel GmbH and Weleda AG, it is primarily used for the treatment of seasonal allergic rhinitis (hay fever) and other allergic disorders. The preparation is designed to modulate immunological pathways involved in allergic responses; in vitro studies suggest that the Citrus component selectively reduces allergen-specific chronic inflammatory (TNF-alpha) and Th2 pathway activity (IL-5), while the Cydonia component and the combination product mainly affect the induction of the allergen-specific Th1 pathway (IFN-gamma). It is available in various formulations, including solutions for subcutaneous injection, nasal sprays, and eye drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citrus e fructibus + cydonia e fructibus.